Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 197.50
Bid: 195.00
Ask: 200.00
Change: 42.50 (27.42%)
Spread: 5.00 (2.564%)
Open: 155.00
High: 197.50
Low: 155.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Shareholder Meetings Calendar - Next 7 Days

Mon, 11th May 2020 16:03

Tuesday 12 May
GLI Finance
Macfarlane Group
IWG
Standard Life Aberdeen
HgCapital Trust
Reckitt Benckiser
Fidelity European Values
Wednesday 13 May
Ultra Electronics
Vesuvius
Sanne Group
Dialight
Gym Group
Tritax Big Box REIT
Robert Walters
Foxtons Group
Spirax-Sarco Engineering
Greggs
TP ICAP
Rentokil Initial
Cineworld Group
Marshalls
Xeros Technology (re bid offer)
Thursday 14 May
Safestyle UK
Serco
Direct Line
Next
Computacenter
Prudential
Quilter
Just Eat Takeaway.com
Gresham Technology
Flutter Entertainment
Spire Healthcare Group
Telit Communications
Genel Energy
Cairn energy
Forterra
Triple Point Social Housing REIT
Horizonte Minerals
European Assets Trust
Eurocell
TI Fluid System
Friday 15 May
Gresham House
William Hill
Phoenix Group
Petrofac 
Bank of Ireland Group
Serinus Energy
Signature Aviation
Derwent London
Monday 18 May
Alliance Pharma
Faron Pharmaceuticals
Bank of Georgia
Alcentra European Floating Rate Income Fund
 
Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Feb 2019 12:20

Faron Pharmaceuticals Encouraged By Clever-1 Antibody Study Result

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said new data supports the use of Clever-1 antibodies in re-activating an immune response to tumours.Shares in Faron were up

Read more
19 Dec 2018 11:07

Faron Pharmaceuticals pins some hope to YODA trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals issued interim results from its pharmacokinetic/dynamic 'YODA' study on Wednesday, examining various formulations of recombinant human interferon-beta (IFN-beta).

Read more
14 Dec 2018 15:57

Dosing begins in Faron's study of 'Clevegen' drug

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Friday that the first patient has successfully been dosed in the phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug.

Read more
5 Dec 2018 11:19

WINNERS & LOSERS SUMMARY: Ashtead Falls On US Economic Slowdown Worry

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 2.7%. Japan's Takeda Pharmaceutical

Read more
5 Dec 2018 10:13

Traumakine treatment optimal for particular subgroup, Faron finds

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has identified, by genetic testing, an "optimal subgroup" of acute respiratory distress syndrome (ARDS) patients for Traumakine treatment who showed a substantial reduction in mortality during the INTEREST trial, it announced on Wednesday.

Read more
5 Dec 2018 09:09

Faron Pharmaceuticals Finds "Optimal" Patient Group For Traumakine

LONDON (Alliance News) - Faron Pharmaceuticals Ltd shares jumped on Wednesday as the company said it identified an "optimal" subgroup of patients, with a certain genetic mutation, to be

Read more
3 Dec 2018 10:50

WINNERS & LOSERS SUMMARY: McColl's Retail Plunges After Profit Warning

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 8.9%, Evraz, up 7.8%, up

Read more
3 Dec 2018 10:09

Faron Pharmaceuticals applies to begin Clevegen clinical trials

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that its clinical trial application to conduct a Phase I/II study with 'Clevegen', its wholly-owned novel precision cancer immunotherapy drug in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA).

Read more
6 Nov 2018 16:29

DIRECTOR DEALINGS: Faron Divisional Chief Medical Officer Buys Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said VP Drug Development Chief Medical Officer Matti Karvonen acquired shares in the biopharmaceutical company.In a transaction

Read more
22 Oct 2018 15:32

Faron Reports Corticosteroids Interference In Traumakine Trial

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Monday that it has found evidence suggesting that corticosteroids used in parallel to its Traumakine treatment had a significant effect on a

Read more
17 Sep 2018 10:37

Faron Pharmaceuticals Submits Clinical Trial Application For Clevegen

LONDON (Alliance News) - Faron Pharmaceuticals Oy said Monday it has filed a clinical trial application for its cancer immunotherapy drug Clevegen.Clevegen, an anti-Clever-1 antibody, the a

Read more
13 Sep 2018 10:49

WINNERS & LOSERS SUMMARY: Retailers Hit As John Lewis Profit Collapses

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank a

Read more
13 Sep 2018 10:30

Faron Pharmaceuticals Falls As Interim Loss Widens On Research Costs

LONDON (Alliance News) - Shares in Faron Pharmaceuticals Ltd dropped on Thursday after the company said its loss for the first half of its financial year increased on higher research were trading

Read more
13 Sep 2018 08:36

Faron losses widen following disappointing Traumakine trial

(Sharecast News) - Faron Pharmaceuticals' operating loss doubled in the first half of its trading year following the group's disappointing trial on its Traumakine treatment.

Read more
12 Sep 2018 13:48

Faron Pharmaceuticals Says New Clever-1 Data Shows B Cell Response

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Wednesday that new data from its cell surface receptor Clever-1 showed B cell response control and humoral antibody production.The by

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.